Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Indian J Dermatol Venereol Leprol ; 2019 Nov; 85(6): 664-665
Article | IMSEAR | ID: sea-192536
2.
Indian J Dermatol Venereol Leprol ; 2007 Sep-Oct; 73(5): 323-5
Article in English | IMSEAR | ID: sea-52495

ABSTRACT

BACKGROUND: To date, periorbital melanosis is an ill-defined entity. The condition has been stated to be darkening of the skin around the eyes, dark circles, infraorbital darkening and so on. AIMS: This study was aimed at exploring the nature of pigmentation in periorbital melanosis. METHODS: One hundred consecutive patients of periorbital melanosis were examined and investigated to define periorbital melanosis. Extent of periorbital melanosis was determined by clinical examination. Wood's lamp examination was performed in all the patients to determine the depth of pigmentation. A 2-mm punch biopsy was carried out in 17 of 100 patients. RESULTS: In 92 (92%) patients periorbital melanosis was an extension of pigmentary demarcation line over the face (PDL-F). CONCLUSION: Periorbital melanosis and pigmentary demarcation line of the face are not two different conditions; rather they are two different manifestations of the same disease.


Subject(s)
Adult , Child, Preschool , Facial Dermatoses/diagnosis , Female , Humans , Male , Melanosis/diagnosis , Pregnancy , Pregnancy Complications/pathology , Sex Factors , Skin/pathology , Skin Pigmentation
4.
Indian J Dermatol Venereol Leprol ; 2005 Mar-Apr; 71(2): 122-4
Article in English | IMSEAR | ID: sea-52815

ABSTRACT

Proteus syndrome is a complex developmental abnormality. It is characterized by both hypertrophic and hypoplastic changes. Deformities have been occasionally found to be localized in one half of the body in head or digit but presence of all signs in one half of the body in a wide spread manner is not reported in the literature. We report the case for its unusual presentation of unilateral localization of signs.


Subject(s)
Adult , Diagnosis, Differential , Female , Humans , Proteus Syndrome/diagnosis
7.
Indian J Dermatol Venereol Leprol ; 2004 May-Jun; 70(3): 156-8
Article in English | IMSEAR | ID: sea-52914

ABSTRACT

BACKGROUND: Punch grafting followed by PUVA/PUVASOL is an established mode of therapy in vitiligo including that on the lips. AIMS: To assess the efficacy of NB-UVB along with regrafting in patients in whom punch grafting had failed to evoke any response. METHODS: Five patients with stable and isolated lip vitiligo in whom punch grafting and PUVA had failed to produce pigmentation were treated by regrafting and subsequent NB-UVB (311 nm) phototherapy. RESULTS: Complete repigmentation was observed in three of the five cases after 16 weeks. In the remaining two, the results were mixed. CONCLUSIONS: Stable lip vitiligo usually responds very well to punch grafting and PUVA/PUVASOL. In patients who fail to respond to this treatment, complete repigmentation following regrafting and NB-UVB is an observation that needs to be explained.

8.
Indian J Dermatol Venereol Leprol ; 2004 Jan-Feb; 70(1): 43-4
Article in English | IMSEAR | ID: sea-52275
9.
Indian J Dermatol Venereol Leprol ; 2002 Mar-Apr; 68(2): 106-7
Article in English | IMSEAR | ID: sea-52782

ABSTRACT

Chevron nail is a nail surface pattern where V-shaped bar or bars are present on the nail plate. We describe 3 patients having atopy associated with this new nail pattern.

10.
Indian J Dermatol Venereol Leprol ; 2002 Mar-Apr; 68(2): 73-6
Article in English | IMSEAR | ID: sea-52556

ABSTRACT

Five hundred and twelve patients with chronic idiopathic urticaria (CIU) were treated with fexofenadine at a dose on 180 mg/day. Maximum number of patients were between 20 to 40 years of age and female to male ratio was 1.45:1. The severity of itching was calculated on a scale of 0 to 4 and was recorded by the patients. The mean daily total symptom score (TSS) was measured as sum of the patients' pruritus and number of wheal scores (0 to 7). A mean TSS was determined for each week. Baseline TSS came down to '0' by 4 weeks in all groups except those with TSS 4. There was no correlation between the baseline TSS and degree of improvement. Of 512, 14 (2.73%) patients did not complete the study. The commonest adverse effect was headache (9.04%). There was no report of drowsiness or cardiac arrhythmia. In no patient fexofenadine had to be withdrawn because of its adverse effects.

SELECTION OF CITATIONS
SEARCH DETAIL